文献速递免疫规划

完成四剂Sabin株或野毒株脊髓灰质炎灭活疫苗的4岁儿童免疫原性与免疫持久性:一项IV期、开放标签、平行对照观察性研究

Immunogenicity and immune persistence in 4-year-old children completing four doses of Sabin strain or wild strain inactivated poliovirus vaccine: A phase IV, open-labeled, parallel-controlled observational study.
PubMed 文献 · Vaccine · 2023-04-29

该IV期开放标签平行对照观察性研究基于III期临床试验,纳入500名4岁儿童(sIPV组334人,wIPV组166人),评估完成4剂接种后的中和抗体持久性。结果显示所有受试者三个血清型抗体阳性率均100%,sIPV组GMT非劣于wIPV组,结论为4岁时不建议再加强接种。

要点

  • 4岁儿童完成4剂sIPV或wIPV后,三个血清型中和抗体阳性率(≥1:8)均为100.00%。
  • sIPV组抗体GMT在三个血清型均非劣于wIPV组(P < 0.0001)。
  • 从加强接种后1个月至4岁,sIPV组GMT下降10倍、8倍、7倍,wIPV组下降13倍、7倍、7倍。

核心结论

  • 完成四剂sIPV或wIPV的4岁儿童中和抗体水平远高于血清保护阈值(≥1:8),因此4岁时不建议再加强接种。
  • 更长时间的免疫持久性观察仍在进行中。

研究设计与样本

  • IV期、开放标签、平行对照观察性研究,基于III期临床试验,按中国国家药品监督管理局(NMPA)要求设计。
  • 纳入至少450名4岁(48-54月龄)儿童,按2:1比例入组,这些儿童在2、3、4和18月龄时接种了四剂sIPV或wIPV,采集血样进行中和抗体检测。
  • 最终纳入500名4岁儿童,sIPV组334人,wIPV组166人。

主要发现

  • 所有受试者三个血清型中和抗体阳性率(≥1:8)均为100.00%。
  • 4岁时sIPV组与wIPV组GMT分别为:I型1117.33 vs 337.77,II型632.72 vs 267.34,III型1665.98 vs 923.02。
  • sIPV组中和抗体阳性率和GMT在所有三个血清型不同时间点均非劣于wIPV组(P < 0.0001)。
  • 从加强接种后1个月至4岁,sIPV组GMT对I、II、III型分别下降10倍、8倍、7倍,wIPV组分别下降13倍、7倍、7倍。

临床怎么用

  • 作者结论认为4岁时不建议再加强接种。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sabin strain inactivated poliovirus vaccine (hereinafter as "sIPV") has been marketed globally in recent years, and more data on its immune persistence are needed. METHODS: This is a phase IV, open-labeled, parallel-controlled observational study based on phase III clinical trial as required by the China National Medical Products Administration (NMPA). At least 450 subjects aged four years (48-54 months) who received four doses at 2, 3, 4 and 18 months of age of sIPV or wild strain poliovirus vaccine (wIPV) in phase III clinical trial enrolled at a 2:1 ratio and collected blood samples for neutralizing antibody testing. RESULTS: A total of 500 subjects of four years old (334 in the sIPV group and 166 in wIPV group) were finally enrolled. The seropositivity rates (≥1:8) of neutralizing antibodies against serotype I-III were all 100.00% in all participants, and the geometric mean titers (GMT) were 1117.33 vs. 337.77 against serotype I, 632.72 vs. 267.34 against serotype Ⅱ, 1665.98 vs. 923.02 against serotype III in the sIPV group and wIPV group respectively at 4 years old. The seropositivity rates and GMTs of neutralizing antibodies in the test group were non-inferior to that of the control group against all three serotypes at different time points (P < 0.0001). The antibody GMT experienced a 10-fold, 8-fold, and 7-fold decline for serotypes I, Ⅱ, and III in the sIPV group, and a 13-fold, 7-fold, and 7-fold decline in the wIPV group from one month after booster vaccination to 4 years old. CONCLUSIONS: The neutralizing antibody level is much higher than the seroprotection cutoff (≥1:8) among children of 4 years old who completed the four-dose vaccination of either sIPV or wIPV. Therefore, another booster vaccination is not recommended at 4 years old. Longer immune persistence observation is still ongoing. REGISTRATION: ClinicalTrials.gov Identifier: NCT04989231.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chu K, Li Y, Yu D, et al. Immunogenicity and immune persistence in 4-year-old children completing four doses of Sabin strain or wild strain inactivated poliovirus vaccine: A phase IV, open-labeled, parallel-controlled observational study. Vaccine. 2023. PMID: 37127526. doi:10.1016/j.vaccine.2023.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。